About Human Papillomavirus Type 18 (HPV18) L1 Recombinant Protein

Human Papillomavirus Type 18 (HPV18) is a high-risk papillomavirus strongly associated with cervical cancer, anogenital cancers, and other HPV-associated malignancies. The L1 protein is the major capsid protein of HPV18 and self-assembles into pentameric capsomeres that form the viral capsid. L1 mediates the initial attachment of the virus to host cells and contains the dominant conformational epitopes recognized by virus-neutralizing antibodies. Because of its high immunogenicity, L1 is the principal antigen used in prophylactic HPV vaccines and is widely utilized in vaccine development, serological assays, and immunological research.

eEnzyme's Human HPV18 L1 Recombinant Protein is produced for research use and is suitable for antibody generation, ELISA development, Western blotting, epitope mapping, protein-protein interaction studies, and vaccine research. This recombinant protein provides a valuable reagent for investigating HPV biology, host immune responses, and the development of next-generation prophylactic vaccines and diagnostic assays.

Applications

Applications

Biological Significance of HPV18 L1

HPV18 L1 is the principal structural protein of the viral capsid and is responsible for forming the highly ordered capsid architecture required for viral infectivity. The L1 protein can self-assemble into virus-like particles (VLPs) that closely resemble native virions but lack viral DNA, making them safe and highly immunogenic vaccine antigens. As the foundation of licensed prophylactic HPV vaccines, Human HPV18 L1 Recombinant Protein provides a valuable research tool for studies of HPV pathogenesis, vaccine development, immune response characterization, and diagnostic assay development.